Little Green Pharma Ltd. · ASX:LGP
Little Green Pharma — H1 FY2021 Earnings Presentation
21 slides from Little Green Pharma's earnings presentation, Feb 24, 2021
Slide 1: Half Yearly Report - Company Update
For personal use only HALF YEARLY REPORT COMPANY UPDATE 24 FEBRUARY 2021
Slide 2: Disclaimer
Disclaimer For personal use only Disclaimer This presentation contains summary information about Little Green Pharma Ltd (ACN 615 586 Forward looking statements 215) (“LGP”) and its activities current as at the date of this presentation. The information in this Certain information in this document r
Slide 3: Financial Performance
Financial Performance Half yearly – 31 December 2020 CASH AT BANK2 For personal use only REVENUE $4.3m 4.4m 31 Dec 2019 $716,046 31 Dec 2020 31 DEC 19 31 DEC 20 $3,771,237 UNITS SOLD AUSTRALIA PROFIT/(LOSS) AFTER TAX 21,000+ 31 Dec 2019 ($5,505,023) 4,850+ 31 Dec 2020 $484,329 31 DEC 19 31 DEC 20 NE
Slide 4: Capital Placement
Capital Placement Funding strategic growth For personal use only Placement Proceeds $22.1 million institutional placement to new and existing institutional and high net worth investors Currently offering a $5 million SPP to eligible shareholders Proceeds of the Placement and SPP enables execut
Slide 5: Corporate Overview
Corporate Overview For personal use only Little Green Pharma Overview Shareholders5 • Vertically integrated medicinal cannabis business with Shareholder Shareholding Ownership operations from cultivation and production through to Elixxer Ltd 28.1m 16.0% manufacturing and distribution Fleta Solomon 1
Slide 6: We are passionate about transforming lives
For personal use only We are passionate about transforming lives. This drives our desire to grow and produce quality cannabis medicines that are safe, effective and affordable. It’s the heart of everything we do and defines our culture. This is our purpose – to reimagine cannabis medicine and do ext
Slide 7: Our Business Model Captures Value
Our Business Model Captures Value LGP operates across the medicinal cannabis supply chain For personal use only Cultivation & Manufacturing Product Patient Access Sales & Production Innovation & Education Distribution Cultivation capacity of ~3t of Internal GMP-licensed Strong brand selling six LGP-
Slide 8: Growth Strategy
Growth Strategy Little Green Pharma has a track record of sales growth with a clear For personal use only pathway to increasing margins and driving significant revenue growth in Australia and offshore markets 1 Established sales platform in Australia 2 Clear pathway to international sales 3 Product
Slide 9: Track Record of Growing Patient Access
Track Record of Growing Patient Access Strong growth in sales and patients using LGP products in Australia For personal use only 40,000 10,000 35,000 $3.8m1 9,000 Revenue (H1FY21) 55.7%2 8,000 up 427% Gross Margin (H1FY21) 30,000 Unique Patients Using LGP Products (#) vs. H1FY20 vs. 56.2% in H1FY20
Slide 10: Capability
For personal use only Capability
Slide 11: Cultivation and Raw Biomass
Cultivation and Raw Biomass For personal use only Option to double cultivation capacity with further expansion if necessary Existing supply lines with multiple suppliers of high- quality third-party raw Indoor GACP cultivation facility capacity re-rated from 1.75t of flower p/a to ~3t material to su
Slide 12: Manufacturing
Manufacturing For personal use only EU-GMP recognition allows LGP to deliver products to countries in Europe and the Americas Additional high-volume manufacturing and R&D capability with exclusive TGA-GMP licensed in-house manufacturing third party GMP facility capable of producing: licensed partner
Slide 13: Strategic Growth
For personal use only Strategic Growth
Slide 14: Patient Acquisition in Australia
Patient Acquisition in Australia Demonstrating market validity For personal use only HIF Entered into strategic partnership with Health Insurance Fund of Australia Partnership (HIF) HIF the first private health insurance fund to publicly support and rebate cannabis medicines HIF to support lar
Slide 15: Clear Pathways to International Sales
Clear Pathways to International Sales Primary target of international brand equity and growth For personal use only France Awarded a primary medicinal cannabis oil supplier role in French government 2-year medicinal cannabis trial in partnership with local distributor Intsel Chimos. Significant beca
Slide 16: Clear Pathways to International Sales
Clear Pathways to International Sales Primary target of international brand equity and growth For personal use only Medicinal cannabis oils now shipped to the UK for patient use UK Cannabis flower to be shipped to UK in near term Working with local distributors to distribute medicines Building out s
Slide 17: Product Innovation
Product Innovation Solving real patient problems For personal use only ARISE The Company has now successfully applied Technology medicinal cannabis to its licensed, patented ARISE delivery technology and is currently undertaking yield optimisation activities before progressing to upscaling and pre-c
Slide 18: News Flow – making solid progress
News Flow – making solid progress Significant commercial progress as LGP executes growth strategy For personal use only Grant of TGA GMP manufacturing licence and commissioning of facility Successful first harvest and capacity increase in expanded facility Partnership with national health insurer Fu
Slide 19: Facility Tour
For personal use only Facility Tour 19
Slide 20: Australian cannabis medicines
For personal use only Australian cannabis medicines
Slide 21: LGP Head Office
For personal use only LGP Head Office PO Box 690, West Perth Western AUSTRALIA 6872 1300 703 999 | +61 8 6280 0050 info@littlegreenpharma.com.au
Little Green Pharma — H1 FY2021 Earnings Presentation on 6ix